Diabetes Care After Transplant Definitions, Risk Factors, and Clinical Management

被引:40
作者
Wallia, Amisha [1 ]
Illuri, Vidhya [1 ]
Molitch, Mark E. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA
关键词
Diabetes; NODAT; Transplant; Transplantation; Kidney; Liver; Immunosuppression; Insulin; RENAL-TRANSPLANTATION; SEVERE HYPOGLYCEMIA; KIDNEY-TRANSPLANT; GLYCEMIC CONTROL; RECEIVING CALCINEURIN; RANDOMIZED-TRIAL; INSULIN THERAPY; MTOR INHIBITOR; CYCLOSPORINE-A; HEPATITIS-C;
D O I
10.1016/j.mcna.2016.01.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients who undergo solid organ transplantation may have preexisting diabetes mellitus (DM), develop new-onset DM after transplantation (NODAT), or have postoperative hyperglycemia that resolves shortly after surgery. Although insulin is usually used to control hyperglycemia in the hospital, following discharge most of the usual diabetes oral and parenteral medications can be used in treatment. However, when there are co morbidities such as impaired kidney or hepatic function, or heart disease, special precautions may be necessary. In addition, drug-drug interactions, such as drugs interacting with CYP3A4 enzyme pathway, require additional consideration because of possible interaction with immunosuppressive drug metabolism.
引用
收藏
页码:535 / +
页数:17
相关论文
共 101 条
[1]   Effect of exenatide on β cell function after islet transplantation in type 1 diabetes [J].
Al Ghofaili, Khalid ;
Fung, Michelle ;
Ao, Ziliang ;
Meloche, Mark ;
Shapiro, R. Jean ;
Warnock, Garth L. ;
Elahi, Darlush ;
Meneilly, Graydon S. ;
Thompson, David M. .
TRANSPLANTATION, 2007, 83 (01) :24-28
[2]   Effect of intraoperative hyperglycemia during liver transplantation [J].
Ammori, John B. ;
Sigakis, Matthew ;
Englesbe, Michael J. ;
O'Reilly, Michael ;
Pelletier, Shawn J. .
JOURNAL OF SURGICAL RESEARCH, 2007, 140 (02) :227-233
[3]  
[Anonymous], 2019, DIABETES CARE, V42, pS1, DOI [10.2337/dc20-Sint, 10.2337/dc19-Sint01, 10.2337/dc19-SINT01, 10.2337/dc20-SINT, 10.2337/dc16-S001]
[4]   Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs [J].
Araki, M ;
Flechner, SM ;
Ismail, HR ;
Flechner, LM ;
Zhou, LM ;
Derweesh, IH ;
Goldfarb, D ;
Modlin, C ;
Novick, AC ;
Faiman, C .
TRANSPLANTATION, 2006, 81 (03) :335-341
[5]   SEVERE HYPOGLYCEMIA DURING TREATMENT WITH GLIPIZIDE [J].
ASPLUND, K ;
WIHOLM, BE ;
LUNDMAN, B .
DIABETIC MEDICINE, 1991, 8 (08) :726-731
[6]   Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality [J].
Baid, S ;
Cosimi, AB ;
Farrell, ML ;
Schoenfeld, DA ;
Feng, S ;
Chung, RT ;
Tolkoff-Rubin, N ;
Pascual, M .
TRANSPLANTATION, 2001, 72 (06) :1066-1072
[7]   PHARMACOKINETICS OF GLIPIZIDE IN MAN - INFLUENCE OF RENAL-INSUFFICIENCY [J].
BALANT, L ;
ZAHND, G ;
GORGIA, A ;
SCHWARZ, R ;
FABRE, J .
DIABETOLOGIA, 1973, 9 :331-338
[8]   Rosiglitazone treatment of diabetes mellitus after solid organ transplantation [J].
Baldwin, D ;
Duffin, KE .
TRANSPLANTATION, 2004, 77 (07) :1009-1014
[9]   A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency [J].
Baldwin, David ;
Zander, Jennifer ;
Munoz, Christina ;
Raghu, Preeya ;
DeLange-Hudec, Susan ;
Lee, Hong ;
Emanuele, Mary Ann ;
Glossop, Valerie ;
Smallwood, Kimberly ;
Molitch, Mark .
DIABETES CARE, 2012, 35 (10) :1970-1974
[10]   Evidence for Rapamycin Toxicity in Pancreatic β-Cells and a Review of the Underlying Molecular Mechanisms [J].
Barlow, Adam D. ;
Nicholson, Michael L. ;
Herbert, Terry P. .
DIABETES, 2013, 62 (08) :2674-2682